2Tamsma J. The pathogenesis of malignant ascites [J]. Cancer Treat Res, 2007,134 ( 1 ) : 109.
3Wornle M, Sauter M, Kastenmtiller K, et al. Role of viral induced vas- cular endothelial growth factor(VEGF) production in pleural effusion and malignant mesothelioma [ J ]. Cell Biol Int,2009,33 (2) : 180.
5Smith EM, Jayson GC. The current and future management of malignant ascites [ J ]. Clin Oncol ( R Coll Radiol) , 2003, 15 (2) :59 -72.
6Runyon BA. Care of patients with ascites[ J ]. N Engl J Med, 1994, 330(5) :337 -342.
7Ayantunde AA, Parsons SL. Pattern and prognostic factors in patients with malignant ascites: a retrospective study[ J]. Ann Oncol, 2007, 18(5) :945 -949.
8MILANESIO M, MONTI E,GARIBOLDI MB,et al. Trend in cy- totoxic activity of a series of cis-[ AptC2 ] ( A = ethylenediamine methylated at different positions) complexes [ J ]. Inorganica Chimica Acta,2008 ,361:2803 -2814.
9DESOIZE B ,MADOULET C. Particular aspects of platinum com- pounds used at present in cancer treatment [ J ]. Crit Rev Oncol Hemato1,2002,42 ( 3 ) : 317 - 325.
10PELEG-SHULMAN T, KATZHENDLER J, GIBSON D. Effects of monofunctional platinum binding on the thermal stability and con- formation of a self-complementary 22-mer[ J]. J Inorg Biochem, 2000,81 (4) :313 - 323.
